← Research library

Neuropeptide immunocorrection in patients with multiple sclerosis

Comparison in people · 2025

What was studied
63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone
Main finding
After three courses, the authors report upper-limb motor-score gains of 1.4 versus 0.8 points and lower-limb gains of 1.8 versus 0.9, with reported p<0.05. The proportion described as having reduced work capacity fell from 71.7% to 31.1% with adjunct Cortexin, versus 75.5% to 53.1% in controls. These are reported functional signals, not evidence of disease modification.

p<0.05 as reported

Reported findings and study design

63 adults with MS aged 18–59: standard care plus Cortexin 33 versus standard care 30; results reported after three courses.

Population or model 63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone

Results · Previously reviewed full-article motor table and reported work-capacity percentages
MeasureResultComparison, timing and statistics
Upper-limb motor-score gain1.4 versus 0.8 pointsp<0.05 as reported
Lower-limb motor-score gain1.8 versus 0.9 pointsp<0.05 as reported
Reduced-work-capacity proportion, add-on arm71.7% → 31.1%
Reduced-work-capacity proportion, comparison arm75.5% → 53.1%

Existing full-article extraction; the motor scale and variance are not adequately specified, and percentages lack raw counts. No MRI, relapse or EDSS progression benefit is established.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Small comparison with unclear allocation, baseline comparability, concomitant therapy and assessment timing; no placebo or blinding described.
  • Motor scale, variance and statistical methods are insufficiently specified. Percentages lack underlying counts; immune-marker claims have no numerical table.
  • No longitudinal MRI lesion, relapse-rate or EDSS progression outcomes are reported. Safety reporting is insufficient; this does not establish an MS treatment or replacement for disease-modifying therapy.
  • A same-title 2021 Artykova–Rakhmatov report exists; cohort overlap remains unresolved and is not counted as independent replication.

Related publications may describe some of the same participants or experiments.

Source details

Open-access journal PDF; Zenodo repository

Methods, results, tables and references reviewed. Randomization, blinding and allocation procedures are not described; this is not classified as a randomized trial.

Full article read; motor table visually checked

Sources checked

Citation

Human comparative studyFull text available

M. A. Artykova, S. A. Beknazarov. Neuropeptide immunocorrection in patients with multiple sclerosis Scientific and Innovative Therapy. 2025;(2):3–9. Bukhara State Medical Institute; Zenodo deposit 5 June 2025

Study source ↗ · DOI 10.5281/zenodo.15635394 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards